Genome-environment interactions in the molecular pathogenesis of dilated cardiomyopathy

Journal of Molecular Medicine

Volumn 83, Issue 8, 2005, Pages 579-586

  Poller, W ^a   Kuhl U ^a   Tschoepe, C ^a   Pauschinger, M ^a   Fechner, H ^a   Schultheiss, H P ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cardiotropic viruses; Dilated cardiomyopathy; Molecular genetics

Indexed keywords

CONGESTIVE CARDIOMYOPATHY; ENVIRONMENT; ENVIRONMENTAL FACTOR; GENE EXPRESSION; GENE IDENTIFICATION; GENE INTERACTION; GENE LOCUS; GENOMICS; HEART MUSCLE BIOPSY; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE; HEREDITY; HUMAN; PATHOGENESIS; PHENOTYPE; PREVALENCE; PROTEIN STRUCTURE; REVIEW; STRESS; VIRUS; VIRUS CELL INTERACTION;

CARDIOMYOPATHY, DILATED; DISEASE PROGRESSION; GENOME, VIRAL; HUMANS;

EID: 23844518111     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00109-005-0664-2     Document Type: Review

References (71)

1. Eriksson S (1964) Pulmonary emphysema and α1-antitrypsin deficiency. Acta Med Scand 175:197-205
2. Crystal R (1990) α1-antitrypsin deficiency, emphysema, and liver disease. J Clin Invest 85:1343-1352
3. Poller W, Faber J-P, Olek K (1990) Highly variable clinical course in severe α1-antitrypsin deficiency - use of polymerase chain reaction for the detection of rare deficiency alleles. Klin Wochenschr 68:857-863
4. Stecenko A, Brigham K (2003) Gene therapy progress and prospects: α1 antitrypsin. Gene Ther 10:95-99
5. Eriksson S, Carlson J, Veley R (1986) Risk of cirrhosis and primary liver cancer in α1-antitrypsin deficiency. N Engl J Med 314:736-739
6. Teckman J, Qu D, Perlmutter D (1996) Molecular pathogenesis of liver disease in α1-antitrypsin deficiency. Hepatology 24:1504-1516
7. Wu Y, Whitman I, Molmenti E, Moore K, Hippenmeyer P, Perlmutter D (1994) A lag in intracellular degradation of mutant α1-antitrypsin correlates with the liver disease phenotype in homozygous PI ZZ α1-antitrypsin deficiency. Proc Natl Acad Sci U S A 91:9014-9018
8. Franz W, Muller O, Katus H (2001) Cardiomyopathies: from genetics to the prospect of treatment. Lancet 358:1627-1637
9. Sylvius N, Duboscq-Bidot L, Bouchier C et al (2003) Mutational analysis of the β- and δ-sarcoglycan genes in a large number of patients with familial and sporadic dilated cardiomyopathy. Am J Med Genet 120A:8-12
10. Sebillon P, Bouchier C, Bidot L et al (2003) Expanding the phenotype of LMNA mutations in dilated cardiomyopathy and functional consequences of these mutations. J Med Genet 40:560-567
11. Mogensen J, Murphy R, Shaw T et al (2004) Severe disease expression of cardiac troponin C and T mutations in patients with dilated cardiomyopathy. J Am Coll Cardiol 44:2033-2040
12. Kärkkäinen S, Heliö T, Miettinen R et al (2004) A novel mutation, Ser143Pro, in the lamin A/C gene is common in Finnish patients with familial dilated cardiomyopathy. Eur Heart J 25:885-893
13. Gomes A, Potter J (2004) Molecular and cellular aspects of troponin cardiomyopathies. Ann N Y Acad Sci 1015:214-224
14. Mogensen J, Kubo T, Duque M et al (2003) Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. J Clin Invest 111:209-216
15. Murphy R, Mogensen J, Shaw A, Kubo T, Hughes S, McKenna W (2004) Novel mutation in cardiac troponin I in recessive idiopathic dilated cardiomyopathy. Lancet 363:371-372
16. Brito D, Richard P, Isnard R, Pipa J, Komajda M, Madeira H (2003) Familial hypertrophic cardiomyopathy: the same mutation, different prognosis. Comparison of two families with a long follow-up. Rev Port Cardiol 22:1445-1461
17. Knöll R, Hoshijima M, Hoffman H et al (2002) The cardiac mechanical stretch sensor machinery involves a Z disc complex that is defective in a subset of human dilated cardiomyopathy. Cell 111:943-955
18. Mahon N, Madden B, Caforio A et al (2002) Immunohistologic evidence of myocardial disease in apparently healthy relatives of patients with dilated cardiomyopathy. J Am Coll Cardiol 39:455-462
19. Bowles N, Richardson P, Olsen E, Archard L (1986) Detection of coxsackie-B virus-specific RNA sequences in myocardial biopsy samples from patients with myocarditis and dilated cardiomyopathy. Lancet 1:1120-1123
20. Pauschinger M, Doerner A, Kuehl U et al (1999) Enteroviral RNA replication in the myocardium of patients with left ventricular dysfunction and clinically suspected myocarditis. Circulation 99:889-895
21. Kühl U, Pauschinger M, Schwimmbeck P et al (2003) Interferon-β treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 107:2793-2798
22. Frustaci A, Chimenti C, Calabrese F, Pieroni M, Thiene G, Maseri A (2003) Immunosuppressive therapy for active lymphocytic myocarditis: virologic and immunologic profile of responders versus non-responders. Circulation 107:857-863
23. Bowles N, Towbin J (2000) Molecular aspects of myocarditis. Curr Infect Dis Rep 2:308-314
24. Kühl U, Pauschinger M, Bock T et al (2003) Parvovirus B19 infection mimicking acute myocardial infarction. Circulation 108:945-950
25. Bültmann B, Klingel K, Sotlar K et al (2003) Fatal parvovirus B19-associated myocarditis clinically mimicking ischemic heart disease: an endothelial cell-mediated disease. Human Pathol 23:92-95
26. Kühl U, Pauschinger M, Noutsias M et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with "idiopathic" left ventricular dysfunction. Circulation, in press
27. Richardson P, McKenna W, Bristow M et al (1996) Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation 93:841-842
28. Dec G, Palacios I, Fallon J et al (1985) Active myocarditis in the spectrum of acute dilated cardiomyopathies. Clinical features, histological correlates and clinical outcome. N Engl J Med 312:885-890
29. Feldman A, McNamara D (2000) Medical progress: myocarditis. N Engl J Med 343:1388-1398
30. Rohayem J, Dinger J, Fischer R, Klingel K, Kandolf R, Rethwilm A (2001) Fatal myocarditis associated with acute parvovirus B19 and herpesvirus 6 coinfection. J Clin Microbiol 39:4585-4587
31. Nigro G, Bastianon V, Colloridi V et al (2000) Human parvovirus B19 infection in infancy associated with acute and chronic lymphocytic myocarditis and high cytokine levels: report of 3 cases and review. Clin Infect Dis 31:65-69
32. Murry C, Jerome K, Reichenbach D (2001) Fatal parvovirus myocarditis in a 5-year-old girl. Human Pathol 32:342-345
33. Yoshikawa T, Ihira M, Suzuki K et al (2001) Fatal acute myocarditis in an infant with human herpesvirus 6 infection. J Clin Pathol 54:792-795
34. Pankuweit S, Moll R, Baandrup U, Portig I, Hufnagel G, Maisch B (2003) Prevalence of the parvovirus B19 genome in endomyocardial biopsy specimens. Human Pathol 94:497-500
35. Klingel K, Kandolf R (1993) The role of enterovirus replication in the development of acute and chronic heart muscle disease in different immunocompetent mouse strains. Scand J Infect Dis Suppl 88:79-85
36. Shioi T, Matsumori A, Sasayama S (1996) Persistent expression of cytokine in the chronic stage of viral myocarditis in mice. Circulation 94:2930-2937
37. Horwitz M, LaCava A, Fine C, Rodriguez E, Ilic A, Sarvetnick N (2000) Pancreatic expression of interferon-γ protects mice from lethal coxsackievirus B3 infection and subsequent myocarditis. Nat Med 6:693-697
38. Tschöpe C, Bock C, Kasner M et al. High prevalence of cardiac parvovirus B19 infection in patients with isolated left ventricular diastolic dysfunction. Circulation, in press
39. 5 on the cardiomyocyte sarcolemma and upregulated in dilated cardiomyopathy - implications for cardiotropic viral infections. Circulation 104:275-280
40. Fechner H, Noutsias M, Tschoepe C et al (2003) Induction of coxsackievirus-adenovirus-receptor expression during myocardial tissue formation and remodeling - identification of a cell-cell contact dependent regulatory mechanism. Circulation 107:876-882
41. Gaggar A, Shayakhmetov D, Lieber A (2003) CD46 is a cellular receptor for group B adenoviruses. Nat Med 9:1408-1412
42. Ulevitch R (2004) Therapeutics targeting the innate immune system. Nat Rev Immunol 4:512-520
43. Liu P, Aitken K, Kong YY et al (2000) The tyrosine kinase p56lck is essential in coxsackievirus B3-mediated heart disease. Nat Med 6:429-434
44. Deonarain R, Cerullo D, Fuse K, Liu P, Fish E (2004) Protective role for interferon-β in coxsackievirus B3 infection. Circulation 110 (in press)
45. Opavsky M, Martino T, Rabinovitch M et al (2002) Enhanced ERK-1/2 activation in mice susceptible to coxsackievirus-induced myocarditis. J Clin Invest 109:1561-1569
46. Badorff C, Lee G, Iamphear B et al (1999) Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat Med 5:320-326
47. Xiong D, Lee G-H, Badorff C et al (2002) Dystrophin deficiency markedly increases enterovirus-induced cardiomyopathy: a genetic predisposition to viral heart disease. Nat Med 8:782-877
48. Eigenthaler M, Engelhardt S, Schinke B et al (2003) Disruption of cardiac Ena-VASP protein localization in intercalated disks causes dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 285:H2471-H2481
49. Arimura T, Hayashi T, Terada H et al (2004) A Cypher/ZASP mutation associated with dilated cardiomyopathy alters the binding affinity to protein kinase C. J Biol Chem 279:6746-6752
50. Zemljic-Harpf AE, Ponrartana S, Avalos RT et al (2004) Heterozygous inactivation of the vinculin gene predisposes to stress-induced cardiomyopathy. Am J Pathol 165:1033-1044
51. Hamada H, Suzuki M, Yuasa S et al (2004) Dilated cardiomyopathy caused by aberrant endoplasmic reticulum quality control in mutant KDEL receptor transgenic mice. Mol Cell Biol 24:8007-8017
52. Kamisago M, Solomon S, Sharma P et al (2000) Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy. N Engl J Med 343:1688-1696
53. Bonne G, Carrier L, Richard P, Hainque B, Schwartz K (1998) Familial hypertrophic cardiomyopathy: from mutations to functional defects. Circ Res 83:580-593
54. Olson T, Michels V, Thibodeau S, Tai Y-S, Keating M (1998) Actin mutations in dilated cardiomyopathy, a heritable form of heart failure. Science 280:750-752
55. Mogensen J, Klausen IC, Pedersen AK et al (1999) α-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy. J Clin Invest 103:R39-R43
56. Li D, Czernuszewicz GZ, Gonzalez O et al (2001) Novel cardiac troponin T mutation as a cause of familial dilated cardiomyopathy. Circulation 104:2188-2193
57. Hoffmann B, Schmidt-Traub H, Perrot A, Osterziel KJ, Gessner R (2001) First mutation in cardiac troponin C, L29Q, in a patient with hypertrophic cardiomyopathy. Human Mutat 17:524
58. Olson T, Kishimoto N, Whitby F, Michels V (2001) Mutations that alter the surface charge of alpha-tropomyosin are associated with dilated cardiomyopathy. J Mol Cell Cardiol 33:723-732
59. Thierfelder L, Watkins H, MacRae C et al (1994) α-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell 77:701-712
60. Gerull B, Gramlich M, Atherton J et al (2002) Mutations of TTN, encoding the giant muscle filament titin, cause familial dilated cardiomyopathy. Nat Genet 30:201-204
61. Itoh-Satoh M, Hayashi T, Nishi H et al (2002) Titin mutations as the molecular basis for dilated cardiomyopathy. Biochem Biophys Res Commun 291:385-393
62. Mohapatra B, Jimenez S, Lin JH et al (2003) Mutations in the muscle LIM protein and α-actinin-2 genes in dilated cardiomyopathy and endocardial fibroelastosis. Mol Genet Metab 80:207-215
63. Tsubata S, Bowles KR, Vatta M et al (2000) Mutations in the human d-sarcoglycan gene in familial and sporadic dilated cardiomyopathy. J Clin Invest 106:655-662
64. Maeda M, Holder E, Lowes B, Valent S, Bies R (1997) Dilated cardiomyopathy associated with deficiency of the cytoskeletal protein metavinculin. Circulation 95:17-20
65. Li D, Tapscoft T, Gonzalez O et al (1999) Desmin mutation responsible for idiopathic dilated cardiomyopathy. Circulation 100:461-464
66. Goldfarb LG, Park KY, Cervenakova L et al (1998) Missense mutation in desmin associated with familial cardiac and skeletal myopathy. Nat Genet 19:402-403
67. Fatkin D, MacRae C, Sasaki T et al (1999) Missense mutations in the rod domain of the lamin A/C gene as caused of dilated cardiomyopathy and conduction-system disease. N Engl J Med 341:1715-1724
68. Schmitt J, Kamisago M, Asahi M et al (2003) Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science 299:1410-1413
69. Haghighi K, Kolokathis F, Pater L et al (2003) Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J Clin Invest 111:869-876
70. Forleo C, Resta N, Sorrentino S et al (2004) Association of β-adrenergic receptor polymorphisms and progression to heart failure in patients with idiopathic dilated cardiomyopathy. Am J Med 117:451-458
71. Mizon-Gerard F, de Groote P, Lamblin N et al (2004) Prognostic impact of matrix metalloproteinase gene polymorphisms in patients with heart failure according to the aetiology of left ventricular systolic dysfunction. Eur Heart J 25:688-693